Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

101. Anticoagulant treatment for subsegmental pulmonary embolism. (PubMed)

Anticoagulant treatment for subsegmental pulmonary embolism. Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its rate (...) PEs. However, the clinical significance in patients and their prognosis have to be studied to evaluate whether anticoagulation therapy is required.This review is an update of a Cochrane systematic review first published in 2014.To assess the effectiveness and safety of anticoagulation therapy versus no intervention in patients with isolated subsegmental pulmonary embolism (SSPE) or incidental SSPE.The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched

2016 Cochrane

102. Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates?

Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates? Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ Article Text Original EBM Research Avoiding alert fatigue in pulmonary embolism

2016 Evidence-Based Medicine (Requires free registration)

103. Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death?

Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death? Systematic Review Snapshot TAKE-HOME MESSAGE Five pulmonary embolism clinical prediction rules to predict early all-cause mortality have sensitivities greater than 88%, but only 3 are supported by a high level of evidence. The simpli?ed Pulmonary Embolism Severity Index appears to have the greatest potential, given its relatively higher sensitivity and ease (...) of use. Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Suf?cient Sensitivity to Identify Patients at Very Low Risk of Death? EBEM Commentators Brit J. Long, MD Department of Emergency Medicine SAUSHEC Fort Sam Houston, TX Alex Koyfman, MD Department of Emergency Medicine UT Southwestern Medical Center/Parkland Memorial Hospital Dallas, TX Results Thesystematicreviewidenti?ed 40 studies reporting on 11 different clinical prediction rules, with the majorityreportingonasinglerule;4

2016 Annals of Emergency Medicine Systematic Review Snapshots

104. Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy?

Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy? TAKE-HOME MESSAGE There is evidence to suggest a small mortality bene?t with the administration of thrombolytics for hemodynamically stable pulmonary embolism patients with right ventricular strain, but this bene?t must be weighed against the signi?cantly increased risk of major bleeding. Should Patients Who Receive a Diagnosis of Acute (...) Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy? EBEM Commentator Melinda J. Morton, MD, MPH Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore, MD Results Commentary Previous systematic reviews have not consistently reported a reduc- tioninmortalitywiththrombolytic therapy for an unselected popula- tion of patients with pulmonary embolism. 2 The American Heart Association currently recommends that providers

2016 Annals of Emergency Medicine Systematic Review Snapshots

105. Formative assessment and design of a complex clinical decision support tool for pulmonary embolism

Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Formative assessment and design of a complex clinical decision support tool for pulmonary embolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Article Text Methods Formative assessment and design of a complex clinical decision

2016 Evidence-Based Medicine (Requires free registration)

106. Suspected Pulmonary Embolism

Suspected Pulmonary Embolism Revised 2016 ACR Appropriateness Criteria® 1 Suspected Pulmonary Embolism American College of Radiology ACR Appropriateness Criteria ® Suspected Pulmonary Embolism Variant 1: Suspected pulmonary embolism. Intermediate probability with a negative D-dimer or low pretest probability. Radiologic Procedure Rating Comments RRL* X-ray chest 9 ? CTA chest with IV contrast 5 This procedure should be optimized for pulmonary arterial enhancement. This procedure may (...) contrast 2 O US echocardiography transthoracic resting 2 O CT chest without and with IV contrast 1 ??? Arteriography pulmonary with right heart catheterization 1 ???? MRA chest without IV contrast 1 O US echocardiography transesophageal 1 O Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Suspected Pulmonary Embolism Variant 2: Suspected pulmonary embolism. Intermediate probability with a positive

2016 American College of Radiology

107. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. (PubMed)

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Pulmonary embolism is a potentially life-threatening condition in which a clot can travel from the deep veins, most commonly in the leg, up to the lungs. Previously, a pulmonary embolism was treated with the anticoagulants heparin and vitamin K antagonists. Recently, however, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTI) and oral (...) of pulmonary embolism.The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched January 2015) and the Cochrane Register of Studies (last searched January 2015). Clinical trials databases were also searched for details of ongoing or unpublished studies. We searched the reference lists of relevant articles retrieved by electronic searches for additional citations.We included randomised controlled trials in which patients with a pulmonary embolism confirmed by standard

2015 Cochrane

108. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

2015 BestBETS

109. Thrombolytic therapy for pulmonary embolism. (PubMed)

Thrombolytic therapy for pulmonary embolism. Thrombolytic therapy (powerful anticoagulation drugs) is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is the second update (...) pulmonary embolism compared with heparin. Furthermore, thrombolytic therapies included in the review were heterogeneous. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause more major and minor haemorrhagic events and stroke. More high quality double blind RCTs assessing safety and cost-effectiveness are required.

Full Text available with Trip Pro

2015 Cochrane

110. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. (PubMed)

Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Pulmonary embolism (PE) can be a severe disease and is difficult to diagnose, given its nonspecific signs and symptoms. Because of this, testing patients with suspected acute PE has increased dramatically. However, the overuse of some tests, particularly computed tomography (CT) and plasma d-dimer measurement, may not improve care (...) for this paper is all clinicians; the target patient population is all adults, both inpatient and outpatient, suspected of having acute PE.Clinicians should use validated clinical prediction rules to estimate pretest probability in patients in whom acute PE is being considered.Clinicians should not obtain d-dimer measurements or imaging studies in patients with a low pretest probability of PE and who meet all Pulmonary Embolism Rule-Out Criteria.Clinicians should obtain a high-sensitivity d-dimer measurement

Full Text available with Trip Pro

2015 Annals of Internal Medicine

111. Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy?

Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? BestBets: Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? Report By: Chris Morgan, Hyun Choi - TBC Institution: University of Manchester, Manchester, UK and Emergency Department, Lewisham and Greenwich NHS Trust, London, UK Date Submitted (...) : 26th August 2015 Last Modified: 26th August 2015 Status: Green (complete) Three Part Question In [a symptomatic patient with an isolated subsegmental pulmonary embolism] does [anticoagulation therapy or no treatment] lead to [lower rates of mortality and recurrent venous thromboembolism?] Clinical Scenario A 62-year-old gentleman attends your Emergency Department with shortness of breath and chest pain. You suspect a pulmonary embolism (PE) and request a CT pulmonary angiogram. The radiologist

2015 BestBETS

112. Fibrinolysis for patients with intermediate-risk pulmonary embolism

Fibrinolysis for patients with intermediate-risk pulmonary embolism PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

113. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism Edo Edoxaban for treating and for pre xaban for treating and for prev venting enting deep v deep vein thrombosis and pulmonary ein thrombosis and pulmonary embolism embolism T echnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta354 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) , to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate (TA354) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

114. Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism (PubMed)

Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism For patients with acute symptomatic pulmonary embolism (PE), the Bova score classifies their risk for PE-related complications within 30 days after diagnosis. The original Bova score was derived from 2,874 normotensive patients with acute PE who participated in one of six prospective PE studies.We retrospectively assessed the validity

2015 EvidenceUpdates

115. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. (PubMed)

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain.To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist.Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 (...) months); 371 adult patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist were randomized and followed up between July 2007 and September 2014 in 14 French centers.Warfarin or placebo for 18 months.The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months after randomization. Secondary

Full Text available with Trip Pro

2015 JAMA Controlled trial quality: predicted high

116. Comparison of Wells and Revised Geneva Rule to Assess Pretest Probability of Pulmonary Embolism in High-Risk Hospitalized Elderly Adults (PubMed)

Comparison of Wells and Revised Geneva Rule to Assess Pretest Probability of Pulmonary Embolism in High-Risk Hospitalized Elderly Adults To assess and compare the diagnostic power for pulmonary embolism (PE) of Wells and revised Geneva scores in two independent cohorts (training and validation groups) of elderly adults hospitalized in a non-emergency department.Prospective clinical study, January 2011 to January 2013.Unit of Internal Medicine inpatients, University of Catania, Italy.Elderly

2015 EvidenceUpdates

117. Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism

Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism Prescrire IN ENGLISH - Spotlight ''In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism'', 1 June 2015 {1} {1} {1} | | > > > In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism FREE DOWNLOAD In the New Products section of the June issue: compared with adjusted-dose warfarin, dabigatran provides no tangible advantages for patients with pulmonary embolism or deep vein thrombosis. Warfarin remains the standard drug. Full text available for free download. Summary The anticoagulant dabigatran

2015 Prescrire

118. Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism

Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism Ultr Ultrasound-enhanced, catheter-directed asound-enhanced, catheter-directed thrombolysis for pulmonary embolism thrombolysis for pulmonary embolism Interventional procedures guidance Published: 26 June 2015 nice.org.uk/guidance/ipg524 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) thrombolysis for pulmonary embolism raises no major safety concerns over those of catheter-directed thrombolysis (CDT) alone. With regard to efficacy, evidence of any enhancement of thrombolysis over CDT alone is inadequate in quality © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 8and quantity. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit

2015 National Institute for Health and Clinical Excellence - Interventional Procedures

119. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism Apixaban for the treatment and Apixaban for the treatment and secondary pre secondary prev vention of deep v ention of deep vein ein thrombosis and/or pulmonary embolism thrombosis and/or pulmonary embolism T echnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341) © NICE 2018. All rights reserved

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

120. Prognostic value of troponins in acute nonmassive pulmonary embolism: A meta-analysis. (PubMed)

Prognostic value of troponins in acute nonmassive pulmonary embolism: A meta-analysis. The objective of our meta-analysis is to update the evidence on the prognostic value of elevated troponin levels in patient with acute normotensive pulmonary embolism (PE). We did a systematic literature review of database, including Pubmed, EMBASE, and Cochrane. Studies were included if those were done on normotensive patients with acute PE and serum troponin assay was done. The primary end point was short

2015 Heart & lung : the journal of critical care